PE20091402A1 - (-) ACIDO 2-[1-(7-METIL-2-MORFOLIN-4-IL)-4-OXO-4H-PIRIDO[1,2-a]PIRIMIDIN-9-IL)ETILAMINO]BENZOICO Y UNA COMPOSICION FARMACEUTICA QUE LO COMPRENDE - Google Patents

(-) ACIDO 2-[1-(7-METIL-2-MORFOLIN-4-IL)-4-OXO-4H-PIRIDO[1,2-a]PIRIMIDIN-9-IL)ETILAMINO]BENZOICO Y UNA COMPOSICION FARMACEUTICA QUE LO COMPRENDE

Info

Publication number
PE20091402A1
PE20091402A1 PE2009000099A PE2009000099A PE20091402A1 PE 20091402 A1 PE20091402 A1 PE 20091402A1 PE 2009000099 A PE2009000099 A PE 2009000099A PE 2009000099 A PE2009000099 A PE 2009000099A PE 20091402 A1 PE20091402 A1 PE 20091402A1
Authority
PE
Peru
Prior art keywords
morpholin
pyrimidin
ethylamine
oxo
methyl
Prior art date
Application number
PE2009000099A
Other languages
English (en)
Inventor
Ola Fjellstrom
Jan A Lindberg
Shaun Jackson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40899463&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20091402(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20091402A1 publication Critical patent/PE20091402A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

REFERIDA AL COMPUESTO SOLIDO O CRISTALINO (-) ACIDO 2-[1-(7-METIL-2-MORFOLIN-4-IL)-4-OXO-4H-PIRIDO[1,2-a]PIRIMIDIN-9-IL)ETILAMINO]BENZOICO QUE TIENE PICOS DE XRPD DE VALORES d: 6,8, 6,1, 5,9, 4,98, 4,41, 4,26 Y 3,91 Å. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHO COMPUESTO ES INHIBIDOR SELECTIVO DE LA PI 3 QUINASA BETA Y ES UTIL EN EL TRATAMIENTO DE ATEROSCLEROSIS, APOPLEJIA, RESTENOSIS, INFARTO DE MIOCARDIO AGUDO, EMBOLIA PULMONAR, TROMBOSIS VENOSA, ENTRE OTROS
PE2009000099A 2008-01-25 2009-01-23 (-) ACIDO 2-[1-(7-METIL-2-MORFOLIN-4-IL)-4-OXO-4H-PIRIDO[1,2-a]PIRIMIDIN-9-IL)ETILAMINO]BENZOICO Y UNA COMPOSICION FARMACEUTICA QUE LO COMPRENDE PE20091402A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2349808P 2008-01-25 2008-01-25

Publications (1)

Publication Number Publication Date
PE20091402A1 true PE20091402A1 (es) 2009-10-21

Family

ID=40899463

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000099A PE20091402A1 (es) 2008-01-25 2009-01-23 (-) ACIDO 2-[1-(7-METIL-2-MORFOLIN-4-IL)-4-OXO-4H-PIRIDO[1,2-a]PIRIMIDIN-9-IL)ETILAMINO]BENZOICO Y UNA COMPOSICION FARMACEUTICA QUE LO COMPRENDE

Country Status (16)

Country Link
US (1) US20090191177A1 (es)
EP (1) EP2245030A4 (es)
JP (1) JP2011510071A (es)
KR (1) KR20100118977A (es)
CN (1) CN101925601A (es)
AR (1) AR070236A1 (es)
AU (1) AU2009206804A1 (es)
BR (1) BRPI0906805A2 (es)
CA (1) CA2712022A1 (es)
CL (1) CL2009000148A1 (es)
MX (1) MX2010008097A (es)
PE (1) PE20091402A1 (es)
RU (1) RU2010133715A (es)
TW (1) TW200936138A (es)
UY (1) UY31609A1 (es)
WO (1) WO2009093972A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI378933B (en) 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
FR2969613B1 (fr) * 2010-12-23 2013-02-08 Sanofi Aventis Nouveaux derives de 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one, leur preparation et leur utilisation pharmaceutique
FR2969612B1 (fr) * 2010-12-23 2013-02-08 Sanofi Aventis Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one, leur preparation et leur utilisation pharmaceutique
HUE024504T2 (en) 2010-12-23 2016-01-28 Sanofi Sa Pyrimidine derivatives, a process for their preparation and their use in medicine
CN104592222B (zh) * 2014-12-26 2016-08-24 苏州明锐医药科技有限公司 抗血小板药物azd6482的制备方法
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
US20230226070A1 (en) * 2020-05-14 2023-07-20 The Heart Research Institute Ltd Treatment of thrombosis and associated disorders with an anti-platelet agent.
CR20230517A (es) 2021-05-03 2023-11-28 Petra Pharma Corp Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades
AU2022282380B2 (en) 2021-05-27 2025-08-14 Petra Pharma Corporation Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of cancer
TW202329930A (zh) 2021-09-30 2023-08-01 美商佩特拉製藥公司 用於治療疾病之磷酸肌醇3-激酶(pi3k)之異位色烯酮抑制劑
WO2023060262A1 (en) * 2021-10-07 2023-04-13 Relay Therapeutics, Inc. Pi3k-alpha inhibitors and methods of use thereof
TW202334137A (zh) * 2021-11-03 2023-09-01 美商薩諾管理公司 Ｐｉ３ｋ抑制劑及治療癌症之方法
WO2023159155A1 (en) * 2022-02-18 2023-08-24 Pivalent Therapeutics, Inc. Inhibitors of phosphoinositide 3-kinase (pi3k) and uses thereof
US20250263394A1 (en) * 2022-04-24 2025-08-21 InventisBio Co., Ltd. Compounds, preparation methods and uses thereof
CN119894898A (zh) * 2022-09-09 2025-04-25 益方生物科技(上海)股份有限公司 化合物、其制备方法和用途
EP4602043A1 (en) * 2022-10-14 2025-08-20 Genesis Therapeutics, Inc. 4h-pyrido[1,2-a]pyrimidin-4-one derivatives for treating cancer
WO2024099437A1 (en) * 2022-11-11 2024-05-16 Fochon Biosciences, Ltd. Compounds as protein kinase inhibitors
WO2024151759A1 (en) * 2023-01-11 2024-07-18 Synnovation Therapeutics, Inc. HETEROCYCLIC COMPOUNDS AS PI3Kα INHIBITORS
WO2024259491A1 (en) * 2023-06-23 2024-12-26 The Heart Research Institute Ltd New synthesis method
WO2026013052A1 (en) * 2024-07-09 2026-01-15 Institut National de la Santé et de la Recherche Médicale Methods of treating familial adenomatous polyposis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0525123B1 (en) * 1990-06-20 1997-09-17 PHARMACIA & UPJOHN COMPANY Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
AU2001230426C1 (en) * 2000-01-24 2006-06-22 Astrazeneca Ab Therapeutic morpholino-substituted compounds
NZ538420A (en) * 2002-08-16 2007-06-29 Kinacia Pty Ltd Inhibition of phosphoinositide 3-kinase beta

Also Published As

Publication number Publication date
CN101925601A (zh) 2010-12-22
CA2712022A1 (en) 2009-01-30
CL2009000148A1 (es) 2010-10-15
UY31609A1 (es) 2009-08-31
AU2009206804A1 (en) 2009-07-30
WO2009093972A1 (en) 2009-07-30
RU2010133715A (ru) 2012-02-27
BRPI0906805A2 (pt) 2015-07-14
EP2245030A4 (en) 2012-03-21
JP2011510071A (ja) 2011-03-31
MX2010008097A (es) 2010-08-04
KR20100118977A (ko) 2010-11-08
TW200936138A (en) 2009-09-01
US20090191177A1 (en) 2009-07-30
EP2245030A1 (en) 2010-11-03
AR070236A1 (es) 2010-03-25

Similar Documents

Publication Publication Date Title
PE20091402A1 (es) (-) ACIDO 2-[1-(7-METIL-2-MORFOLIN-4-IL)-4-OXO-4H-PIRIDO[1,2-a]PIRIMIDIN-9-IL)ETILAMINO]BENZOICO Y UNA COMPOSICION FARMACEUTICA QUE LO COMPRENDE
HN2008001374A (es) Compuestos de cinamida policiclicos
CY2021016I2 (el) Παραγωγο πολυκυκλικης καρβαμοϋλοπυριδονης με ανασταλτικη ενεργοτητα της ιντεγκρασης του ηiv
LTC3106463I2 (lt) Pakeistieji pirazolo[1,5-a]pirimidino junginiai kaip trk kinazės slopikliai
SV2009002861A (es) Compuestos de pirimidina amida como inhibidores de pgds
SMT201200061B (it) Composti di pirazina come inibitori della fosfodiesterasi 10
DK2350075T3 (da) Substituerede imidazo[1,2b]pyridazinforbindelser som trk-kinase-inhibitorer
NL300650I2 (nl) Olodaterol, het R-enantiomeer daarvan, mengsels van isomeren daarvan, zuuradditiezouten met farmacologisch aanvaardbare zuren daarvan, evenals solvaten en/of hydraten daarvan, in het bijzonder Olodaterol en Olodaterolhydrochloride
NI201000034A (es) Activadores de guanilato ciclasas solubles.
CY1113939T1 (el) Γεφυρωμενες μονοβακταμες xρησιμες ως αναστολεις της βητα-λακταμασης
EP2421537A4 (en) PYRAZOLYLAMINOPYRIDINE AS A FAK HEMMER
AR081946A1 (es) Composicion de limpieza antibacteriana
MA30725B1 (fr) Administration d'inhibiteurs de la dipeptidyl peptidase
DK1888584T3 (da) Tricykliske 1,6-dihydro- 1,3,5,6-tetraaza-as-indacen-baserede forbindelser og farmaceutiske sammensætninger omfattende samme som hæmmere af IKK-enzymaktivitet
CL2014000813A1 (es) El compuesto 1-pirazolil-3-(4-((2-anilinopirimidin-4-il)oxi)naftalen-1-il)urea o sus sales, inhibidor de proteinas cinasas actividas por mitogeno p38; forma sólida cristalina; composicion farmaceutica; combinacion farmaceutica; y su uso en asma, fibrosis quistica, rinitis alergica, psoriasis, entre otras
SMT201400009B (it) Derivati eteroaromatici di ariltriazolo come inibitori dell'enzima pde 10A
WO2006101940A3 (en) Composition comprising n-propanoyl derivatives of amino acids, aminocarbohydrates and derivatives thereof
DK1844008T3 (da) Krystallinske valnemulinsalte med organiske syrer
MX2011008593A (es) Agente limpiador.
ZA201105742B (en) Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as dhodh inhibitor
BRPI0819504A2 (pt) "esponjas de celulose, método para fabricação de um artigo para limpeza antimicobriano e método para manter a habilidade de uma estrutura de limpeza de ser antimicrobiana"
PE20090166A1 (es) Sales de adicion de acido, hidratos y polimorfos de la etil-amida del acido 5-(2,4-dihidroxi-5-isopropil-fenil)-4-(4-morfolin-4-il-metil-fenil)-isoxazol-3-carboxilico, y formulaciones que comprenden estas formas
DOP2010000135A (es) Acido 4-[4-(2-adamantilcarbamoil)-5-tert-butilpirazol-1-il]benzoico-465
NO20073717L (no) Fenylmetanonderivater og deres anvendelse som glycin-transportor-1-inhibitorer
DE07776925T8 (de) Kristalline Form eines nach der Lagerung stabilen Atorvastatin-Calciums

Legal Events

Date Code Title Description
FC Refusal